Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Up 62.5% in January

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant growth in short interest in January. As of January 30th, there was short interest totaling 429 shares, a growth of 62.5% from the January 15th total of 264 shares. Based on an average daily volume of 50,048 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 50,048 shares, the short-interest ratio is presently 0.0 days.

Hedge Funds Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC acquired a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma as of its most recent SEC filing. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Stock Down 3.3%

Shares of MTNB traded down $0.02 during mid-day trading on Friday, reaching $0.59. 28,401 shares of the company’s stock were exchanged, compared to its average volume of 40,874. Matinas Biopharma has a 52-week low of $0.47 and a 52-week high of $3.09. The company has a 50-day simple moving average of $0.67 and a two-hundred day simple moving average of $1.20. The company has a market cap of $3.78 million, a price-to-earnings ratio of -0.17 and a beta of 1.31.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.